Despite advances in understanding the pathogenesis and prevention of atherosclerotic cardiovascular disease, coronary heart disease remains the leading cause of death in the United States. Lipoprotein (a), or Lp(a), is a particularly atherogenic type of lipoprotein, where excess levels significantly influence cardiovascular risk.
This episode will:
The content was current as of the time of recording. To learn more, please review the additional resources below for information on our cardiovascular, metabolic, endocrine, and wellness offerings as well as educational resources and insights from our team of experts. At Quest Diagnostics, we are committed to providing you with results and insights to support your clinical decisions.
Date: 9/10/24
Speaker(s): Maeson Latsko, PhD
Contributor(s): Maeson Latsko, PhD; Trisha Winchester, PhD
Additional Resources:
Ordering information: Lipoprotein (a) | Test Detail | Quest Diagnostics
Lipoprotein(a) | Test Summary | Quest Diagnostics
Quest Diagnostics Clinical Education Center [Link]
References:
Wilson DP, Jacobson TA, Jones PH, et al. Use of Lipoprotein(A) in clinical practice: A biomarker whose time has come. A scientific statement from the National Lipid Association. J Clin Lipidol. 2019;13(3):374-392. doi:10.1016/j.jacl.2019.04.010
Koschinsky ML, Bajaj A, Boffa MB, et al. A focused update to the 2019 NLA scientific statement on use of lipoprotein(a) in clinical practice. J Clin Lipidol. 2024;18(3):e308-e319. doi:10.1016/j.jacl.2024.03.001
